Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices

Similar documents
Film Coating Process Considerations for the Application of High Productivity, High Solids Concentration Film Coating Formulations

Influence of Film Coating Process Parameters on the Gloss of Tablets Coated with Pigmented Aqueous Film Coating Formulations

Effects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS

Amount of individual ingredients added (g) Surelease dispersion*

Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

This document is valid at the time of distribution. Distributed 10-Apr-2018 (UTC) Introduction

Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Pharma Ingredients & Services. Ludiflash. Technical Information

An extended release tablet provides prolonged periods of drug in plasma levels thereby reduce dosing frequency,

Dow Pharma Solutions. ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.

International Journal of Pharmacy

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction

M. Ghimire, P. Patel, Q. Liu, S. Missaghi, S. B. Tiwari, T.P. Farrell and A. R. Rajabi- Siahboomi. Colorcon Ltd

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

FORMULATION AND EVALUATION OF ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE TABLETS

One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation

NISSO HPC for Pharmaceutical Applications

Formulation and Evaluation of Floating Capsules of 3 rd Generation Cephalosporin

Pharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications

FORMULATION AND EVALUATION OF POLYMER EFFECT ON in-vitro KINETICS OF SUSTAINED RELEASE MATRIX TABLETS OF CARVEDILOL USING MODEL DEPENDENT METHODS

Pelagia Research Library

Formulation and in-vitro evaluation of pregabalin mini tablets for sustained release

Co-Processed Lactosebased excipients for Direct Compression. Ulrich Marcher Meggle GmbH & Co. KG, Germany

Soluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services

Novel Floating Pulsatile Approach for Chronotherapeutic Release of Indomethacin

Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION

Research Article. Formulation and in-vitro evaluation of orodispersible tablets of olanzapine for the improvement of dissolution rate

Pelagia Research Library. Design fabrication and characterization of controlled released tablets of Trimetazidine di hydrochloride

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?

Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components

Pharma Ingredients & Services. Kollidon SR. Technical Information

Roller Compaction: New trends, challenges and solutions

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets

Formulation and Evaluation of Gastro retentive Bilayer Tablets- Glimepiride as Sustained Release and Lisinopril as Immediate Release

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Direct compression of cushion layered ethyl cellulose coated extended release pellets into rapidly disintegrating tablets

Formulation of Acetylsalicylic Acid Tablets for Aqueous Enteric Film Coating

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

Process Validation And Risk Assessment Study of Loratadine Tablet

* Current monograph name valid until May 1, 2017 ** New monograph name valid as of May 1, 2012, mandatory as of May 1, 2017

QbD implementation in Generic Industry: Overview and Case-Study

Rajesh Kaza. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,

Formulation and In-Vitro Evaluation of Sustained Release Tablet of Isosorbide -5- Mononitrate by Porous Osmotic Technology

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms

Formulation and Optimization of Taste Masked Rapimelt Dolasteron Mesylate Tablets

Design and Evaluation of Sustained Release Tablets containing Solid dispersion of Ziprasidone hydrochloride

Studies in Prospective Process Validation of Gliclazide Tablet 80 mg Dosage Formulation

Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets

DOW AMBERLITE and DUOLITE Ion Exchange Resin Excipients

Formulation and Evaluation of Oro-Dispersible Tablets Containing Meclizine Hydrochloride

Agilent TRS100 Raman. Quantitative Pharmaceutical Analysis System

Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production

Quan Liu and Reza Fassihi. Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, USA

Maximizing Roller Compaction Benefits with Proper Excipient Selection

PTG-S4 Automated Powder Flow Analyzer

Real-time tablet API analysis: a comparison of a palm-size NIR spectrometer to HPLC method

Development of Sustain Release Matrix Tablet of Ranolazine Based on Methocel K4M CR: In Vitro Drug Release and Kinetic Approach

Formulation and Evaluation of Ranolazine Extended Release Tablets by using ph Dependent and Independent polymers

SUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593

OPTIMIZATION OF OLANZAPINE MOUTH DISSOLVING TABLETS USING MICRONIZATION

Abcite 585 EF. Technical Data and Application Guide. Product description. Typical applications. Product range. Product certifications.

Physico-chemical comparison of famotidine tablets prepared via dry granulation and direct compression techniques

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

FORMULATION AND EVALUATION OF ACECLOFENAC MATRIX TABLETS FOR COLON DRUG DELIVERY

FORMULATION OF TABLET CONTAINING CURCUMIN NANOEMULSION

INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES

Application of USP Apparatus 7 to In Vitro Drug Release in Scopolamine Transdermal Systems

Pharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010

FORMULATION AND EVALUATION OF FLOATING MICROSPHERES OF CEPHALEXIN

DIRECTLY COMPRESSIBLE MEDICATED CHEWING GUM (MCG) FOR STAYING ALERT

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

Coathylene Polymer Powders

Asian Journal of Pharmaceutical and Clinical Research Vol. 3, Issue 4, 2010 ISSN

Pharma Silica Insights

RESEARCH ARTICLE e-issn:

PHARMACEUTICAL MANUFACTURING

SUPAC OF IMMEDIATE-RELEASE, MODIFIED- RELEASE AND SEMI-SOLID: A REGULATORY NOTE

Meeting Solid Dose Formulation Challenges

Drug exhibiting absorption from only a. Design and Clinical Evaluation of Floating Mini Matrix Tablets of Pyridoxine Hydrochloride ORIGINAL ARTICLE

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Effect of Formulation and Process Variables

Discriminating power of dissolution medium in comparative study of solid dispersion tablets of Biopharmaceutics Classification System class 2 drug

Roller Compaction Feasibility for New Drug Candidates

Testosterone 20 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier

Parthiban Kakkatummal Nishad and Natesan Senthil Kumar

Design and Development of Polyethylene Oxide Based Matrix Tablets for Verapamil Hydrochloride

Process validation of clopidogrel bisulphate 75 mg tablets

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

How to Identify Critical Quality Attributes and Critical Process Parameters

BRITISH BIOMEDICAL BULLETIN

Technical brochure FlowLac

Formulation Development and Polymer Optimization for Once-Daily Sustained Release Matrix Tablets of Domperidone

Journal of Pharmaceutical and Scientific Innovation Research Article

ARMEX Blast Media HydroFlex Formula XL Product Code 69061, 69261, , , NSN Page 1 of 5

Silicone Fluids for Modification of Plastics. Peter Stevens Application Development Manager

World Journal of Pharmaceutical Research SJIF Impact Factor 5.990

Transcription:

Surelease Application Data Aqueous Ethylcellulose Dispersion Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices ABSTRACT SUMMARY: In the present study, Surelease, aqueous ethylcellulose dispersion (Colorcon Inc., USA), was used to formulate metformin HCl extended release (ER) inert matrix tablets by fluid bed granulation. All the formulated tablets showed extended drug release properties. The formulation offered the flexibility to modulate the drug release rate by altering the amount of Surelease used during granulation. INTRODUCTION: There has been recent interest in formulating extended release oral dosage forms using inert matrix systems, due to their ease of manufacturing and as an alternative to hydrophilic matrices. 1 Ethylcellulose is commonly used in oral solid dosage forms. It has been used as a binder, a controlled release barrier coating, and as a controlled release matrix in direct compression. 2-3 The use of Surelease as a release retardant binder for the manufacturing of inert matrices has also been reported. 4-5 The objective of the present study was to investigate the applications of Surelease as a release retardant binder in tablet formulations of metformin HCl, a freely soluble drug, applied via fluid bed granulation. Metformin HCl release rates from high and low dose extended release (ER) inert matrices (compressed from Surelease granuled formulation) were studied. EXPERIMENTAL METHODS: The compositions of the inert matrices are shown in Table 1. Granulation was performed using a high (F2) or low (F1) amount of Surelease. Metformin HCl was screened through an ASTM #3 mesh sieve (6 μm), and then fluid bed granulated using a Glatt GPCG-3 fluid bed (Glatt Air Techniques, USA) by top spray. Prior to application, Surelease (25% w/w) was diluted with deionized (DI) water to 15% w/w. Process parameters for fluid bed granulation are shown in Table 2. The dried granules were assessed for bulk and tapped densities using a VanKel density tester (Varian Inc., USA), relative gravimetric flow rates using a SOTAX FT3 flowability tester (SOTAX, USA), particle size distribution (Hosokawa sonic sifter L3P, USA) and loss on drying (LOD) by a moisture balance (Model: IR-2, Denver Instrument, USA). Granules were blended with silicon dioxide, lubricated with magnesium stearate, and were compressed at 5-2 kn using an instrumented 1-station rotary tablet press (PICCOLA, RIVA, Argentina) at 3 rpm. Both granulations (F1 and F2) were compressed at tablet weights of 33 mg and 1 mg, using 9.52 mm standard round concave tooling and 19.5 mm X 9.27 mm caplet tooling, respectively. Tablet weight, breaking force, diameter and thickness were measured Surelease - 1 -

with an automated tablet tester (Multicheck, Erweka, Germany). Tablet friability was measured using a VanKel friability tester (Varian Inc., USA) after 1 revolutions at 25 rpm. Drug release was measured in a USP compliant bath (VK 7, Varian, USA), apparatus II with sinkers, 1 rpm using 1 ml of DI water as dissolution media at 37 C ±.5 C. A uv-visible spectrophotometer (Agilent, USA), operated at a wavelength of 233 nm, was used for detection of metformin HCl. Deionized water was used as reference. Dissolution profiles were characterized using the Higuchi square root of time relationship6: Q = k t1/2, or power law equation4: Q = ktn, where Q is amount of dissolved drug, k is release rate constant, n is the release exponent, and t is dissolution time. Table 1. Formulation of Metformin HCl ER Inert Matrices % Composition Ingredients (w/w) F1 F2 Metformin HCl (Medilom. Co.) 66. 56.6 Surelease NG E-7-195 (Colorcon, Inc.) (on dry basis) 33. 42.4 Silicon dioxide (Cab-O-Sil M- 5P, Cabot Co.).5.5 Magnesium stearate (Mallinckrodt Chemical Inc.).5.5 Total 1. 1. Table 2. Process Parameters for Fluid Bed Granulation Fluid Bed: Glatt GPCG-3 Top spray Batch size (kg) 2.5 Nozzle size (mm) 1.2 Automization pressure (bar) 1.5 Inlet air volume (cfm) 51 79 T inlet (ºC) 8 9 T bed (ºC) 43 46 T oulet (ºC) 39 41 Spray rate (g/min) 2 RESULTS AND DISCUSSION: Surelease granulated formulations exhibited good powder flow as indicated by the low Carr s Index and higher Sotax flowability values (Table 3). The average particle size of granules ranged from 2-3 μm (max. 675 μm). Increasing the amount of Surelease in the granulation resulted in lower tablet hardness irrespective of the total tablet weight or tooling used (Table 4 and Figure 1). Tablet hardness improved with increasing compression force, until a threshold was reached at a compression force of 15 kn (Figure 1). All the tablet formulations exhibited low friability values (Table 4). Surelease - 2 -

Table 3. Physical Properties of Metformin HCl Granules Formula # Bulk density (g/ml) Tapped density (g/ml) Carr s Index (%) SOTAX flow (g/sec) LOD (%) F1.58.66 13.1 16.18.3 F2.55.61 1.1 15.72.57 Table 4. Physical Properties of Metformin HCl ER Tablets Prepared at Compression Force of 15 kn Batch Hardness Friability (kp)* (%) F1 (33 mg) 1.5 ±.2.16 F2 (33 mg) 8.6 ±.1.15 F1 (1 mg) 19.1 ±.5.15 F2 (1 mg) 17. ±.4.17 Figure 1. Effect of Compression Force on Metformin HCl ER Tablet Mechanical Strength (n = 2) Tablet hardness (kp) 2 18 16 14 12 1 8 6 4 2 F1 (33 mg) F1 (1 mg) F2 (33 mg) F2 (1 mg) 5 1 15 2 25 Compression force (kn) Figure 2. Dissolution Profiles of Metformin HCl ER Tablets Prepared at Compression Force of 15 kn 12 1 % Dissolved 8 6 4 2 F1 (33 mg) F1 (1 mg) F2 (33 mg) F2 (1 mg) 2 4 6 8 1 12 14 16 18 2 22 24 Time (hours) All tablet formulations exhibited extended release of the drug (Figure 2). The rate of drug release decreased with increasing Surelease concentration. The smaller tablets (33 mg) showed faster drug release than the larger tablets (1 mg), which could be attributed to the high surface area to volume ratio and shorter diffusional path length of the smaller tablets. Interestingly, all inert matrix tablets stayed intact during and Surelease - 3 -

after dissolution testing. The release data showed good fitting (R2 =.99) to both the Higuchi and power law equation indicating the mechanism of drug release by Fickian diffusion control (Figure 3A & B). Figure 3. Drug Release Data Fitting: (A) Higuchi equation; (B) Power Law Equation. The value of n, the release exponent, ranged from.43 to.54 12 1 A % Dissolved 8 6 4 2 1:.5 (33 mg) 1:.75 (33 mg) 1:.5 (1 mg) 1:.75 (1 mg) 1 2 3 4 5 6 Time 1/2 (hour 1/2 ) 6 5 B Ln(% Dissolved) 4 3 2 1 F1 (33 mg) F2 (33 mg) F1 (1 mg) F2 (1 mg) -1 1 2 3 4 Ln(Time) (Ln(hour)) CONCLUSIONS: Surelease was successfully used to granulate a freely water soluble drug (metformin HCl) and produce extended release inert matrices at high and low dose levels. Fluid bed granulation with Surelease resulted in granules with good flow properties. Inert matrix tablets with good mechanical strength and low friability were achieved at relatively low compression force. The rate of drug release decreased with increasing Surelease concentration. Surelease - 4 -

Powered by TCPDF (www.tcpdf.org) REFERENCES: 1. Tiwari S. and Rajabi-Siahboomi AR. Extended-release oral drug delivery technologies: monolithic matrix systems. In: Drug delivery systems. Totowa, NJ: K.K Jain (Ed), Humana Press, 28; 217-243. 2. Upadrashta SM, Katikaneni PR, Hileman GA, et al. Compressibility and compatibility properties of ethylcellulose. Int. J. Pharm. 1994;112: 173-179. 3. Vass S, Deng H, Rajabi-Siahboomi AR. Investigation of ethylcellulose in the preparation of theophylline extended release inert matrix tablets. AAPS annual meeting and exposition, 28. 4. Ruiz NR, Ghaly ES. Mechanism of drug release from matrices prepared with aqueous dispersion of ethylcellulose. Drug Dev. Ind. Pharm. 1997; 23(1): 113-117. 5. Reyes G, Deng H, Rajabi-Siahboomi AR. Application of ethylcellulose in preparation of extended release theophylline inert matrix tablets by wet granulation. AAPS annual meeting and exposition, 28. 6. Higuchi T. Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 1963; 52: 1145-1148. This ADS has been adapted from the following poster: Quiroga A, Bigatti G, Deng H, Tiwari S, Rajabi_Siahboomi A. Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices. Poster presented at: 36 th Annual Meeting and Exposition of the Controlled Release Society, July 29; Copenhagen, Denmark. The information contained herein, to the best of Colorcon, Inc. s knowledge is true and accurate. Any recommendations or suggestions of Colorcon, Inc. with regard to the products provided by Colorcon, Inc. are made without warranty, either implied or expressed, because of the variations in methods, conditions and equipment which may be used in commercially processing the products, and no such warranties are made for the suitability of the products for any applications that you may have disclosed. Colorcon, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages. Colorcon, Inc. makes no warranty, either expressed or implied, that the use of the products provided by Colorcon, Inc., will not infringe any trademark, trade name, copyright, patent or other rights held by any third person or entity when used in the customer s application. For more information, contact your Colorcon representative or call: North America Europe/Middle East/Africa Asia Pacific Latin America +1-215-699-7733 +44-()-1322-293 +65-6438-318 +54-11-4552-1565 BPSI Holdings LLC, 29. The information contained in this document is proprietary to Colorcon, Inc. and may not be used or disseminated inappropriately. All trademarks, except where noted, are property of BPSI Holdings LLC. ads_invest_aque_ethyl_disp_v1_1.21 You can also visit our website at www.colorcon.com Surelease - 5 -